P-BCMA-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Multiple Myeloma

Active:	Yes
Cancer Type:	Multiple Myeloma	NCT ID:	NCT04960579
Trial Phases:	Phase I	Protocol IDs:	P-BCMA-ALLO1-001 (primary) NCI-2022-02554
Eligibility:	18 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	Poseida Therapeutics, Inc.
NCI Full Details:	http://clinicaltrials.gov/show/NCT04960579

Summary

Phase 1 study comprised of open-label, dose escalation, multiple cohorts of P-BCMA-ALLO1
allogeneic T stem cell memory (Tscm) CAR-T cells in subjects with relapsed / refractory
Multiple Myeloma (RRMM).

Objectives

Phase 1/1b study: Phase 1 Part 1 is a weight-based dose escalation following a 3+3 design
of dose-escalating cohorts. Phase 1 Part 2 includes administration at fixed doses. After
enrollment, subjects may receive a lymphodepletion therapy regimen before administration
of allogeneic CAR-T cells, administered as a single or multiple dose(s). Treated subjects
will undergo serial measurements of safety, tolerability and response. Rimiducid may be
administered as indicated. Phase 1b of the study will undergo further expansion of
cohorts/arms from Phase 1 Parts 1 or 2 or an intermediate dose between cohort levels.

Treatment Sites in Georgia

Winship Cancer Institute of Emory University
1365 Clifton Road NE
Building C
Atlanta, GA 30322
winshipcancer.emory.edu

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.